Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1986;8:1089-1092

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Benetos, A.
Right arrow Articles by Gavras, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benetos, A.
Right arrow Articles by Gavras, H.

Hypertension, Vol 8, 1089-1092, Copyright © 1986 by American Heart Association


ARTICLES

Hypertensive effect of a bradykinin antagonist in normotensive rats

A Benetos, I Gavras and H Gavras

The purpose of these experiments was to study the possible contribution of bradykinin to normal blood pressure maintenance. The bradykinin analogue B4146, a competitive antagonist-partial agonist of bradykinin, was used in three groups of normotensive unanesthetized Wistar rats. Two intra-aortic injections of B4146 (1 mg in 0.2 ml of dextrose) were given 5 minutes apart (i.e., well after return of blood pressure to baseline, which occurred within 68 +/- 19 seconds). One group had been pretreated with the angiotensin converting enzyme inhibitor HOE 498, 1 mg/kg (Hoechst), and one received only dextrose as the first injection to serve as controls. The bradykinin antagonist produced an average increase in mean arterial pressure of approximately 13 mm Hg for all groups. In five animals, however, the first injection of B4146 produced a hypotensive effect, whereas the second one consistently produced a rise in blood pressure. Pretreatment with the angiotensin converting enzyme inhibitor did not affect the magnitude of the subsequent blood pressure increase in response to B4146. Since smaller doses of B4146, sufficient to block exogenous bradykinin, do not cause changes in normal blood pressure, we conclude that endogenous bradykinin does contribute to normal blood pressure maintenance, but its effect can be demonstrated only if very high doses of its antagonist are injected, maybe because a high concentration of the compound is necessary to displace not only circulating but possibly tissue receptor-bound bradykinin as well.


This article has been cited by other articles:


Home page
HypertensionHome page
A. Duka, E. Kintsurashvili, I. Duka, D. Ona, T. A. Hopkins, M. Bader, I. Gavras, and H. Gavras
Angiotensin-Converting Enzyme Inhibition After Experimental Myocardial Infarct: Role of the Kinin B1 and B2 Receptors
Hypertension, May 1, 2008; 51(5): 1352 - 1357.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Duka, I. Duka, G. Gao, S. Shenouda, I. Gavras, and H. Gavras
Role of bradykinin B1 and B2 receptors in normal blood pressure regulation
Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E268 - E274.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
I. Duka, A. Duka, E. Kintsurashvili, C. Johns, I. Gavras, and H. Gavras
Mechanisms Mediating the Vasoactive Effects of the B1 Receptors of Bradykinin
Hypertension, November 1, 2003; 42(5): 1021 - 1025.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
E. Kintsurashvili, I. Duka, I. Gavras, C. Johns, D. Farmakiotis, and H. Gavras
Effects of ANG II on bradykinin receptor gene expression in cardiomyocytes and vascular smooth muscle cells
Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1778 - H1783.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
I. Duka, E. Kintsurashvili, I. Gavras, C. Johns, M. Bresnahan, and H. Gavras
Vasoactive Potential of the B1 Bradykinin Receptor in Normotension and Hypertension
Circ. Res., February 16, 2001; 88(3): 275 - 281.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
N.-E. Rhaleb, X.-P. Yang, M. Nanba, E. G. Shesely, and O. A. Carretero
Effect of Chronic Blockade of the Kallikrein-Kinin System on the Development of Hypertension in Rats
Hypertension, January 1, 2001; 37(1): 121 - 128.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. L. Pasquie, A. Herizi, B. Jover, and A. Mimran
Chronic Bradykinin Infusion and Receptor Blockade in Angiotensin II Hypertension in Rats
Hypertension, March 1, 1999; 33(3): 830 - 834.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
W. R. Fitzgibbon, A. A. Jaffa, R. K. Mayfield, and D. W. Ploth
Role of Kinins in the Renal Response to Enalaprilat in Normotensive and Hypertensive Rats
Hypertension, February 1, 1996; 27(2): 235 - 244.
[Abstract] [Full Text]